Chapter 62 Neurological Disease Serena S. Spudich, MD, Richard W. Price, MD Human immunodeficiency virus (HIV)-1 infection, and particularly its late stage of severe immunodeficiency (acquired immunodeficiency syndrome, AIDS), renders…
Chapter 68 Cardiovascular Disease in HIV Jens D. Lundgren, MD, DMSc, Anette Sjøl, MD Cardiovascular disease (CVD) has emerged as a looming problem for patients infected with HIV, because of…
Chapter 53 International Parasitic Infections Matthew B. Laurens, MD, MPH, Roberto Badaró, MD, PhD, Sanjay Mehta, MD, Constance A. Benson, MD, Miriam K. Laufer, MD, MPH INTRODUCTION HIV and parasitic…
Chapter 65 Oropharyngeal Disease Jeffrey D. Hill, DMD, David Reznik, DDS Oral lesions are common throughout the course of HIV infection. They may represent theinitial signs of infection in the…
Chapter 36 Pneumocystis Pneumonia Laurence Huang, MD, Henry Masur, MD During the first decade of the acquired immunodeficiency syndrome (AIDS) epidemic, Pneumocystis pneumonia (PCP) became widely recognized as the most…
Chapter 61 Wasting Syndrome Jens J. Kort, MD, PhD, Fred R. Sattler, MD INTRODUCTION At the onset of the AIDS epidemic, weight loss and muscle wasting were so intimately linked…
Chapter 81 Adult Antiretroviral Dosing Guidelines Alice K. Pau, PharmD Related posts: Abacavir Human Herpesvirus-6 and Herpesvirus-7 Infections Cryptosporidia, Isospora, and Cyclospora Infections Saquinavir Lipid Disorders Bone Disorders
Chapter 54 Hepatitis B Infection and GB Virus C Ruth Berggren, MD, Holly Murphy, MD HEPATITIS B VIRUS Pathogen Hepatitis B virus (HBV) is a hepatotropic DNA virus of the…
Chapter 4 Strategic Use of Antiretroviral Therapy Michael S. Saag, MD Over the last decade, highly active antiretroviral therapy (HAART) has revolutionized the care of human immunodeficiency virus (HIV) infected…
Chapter 21 Atazanavir Graeme Moyle, MD Atazanavir is a relatively new protease inhibitor (PI) that is dosed once daily with or without ritonavir boosting. Since its approval atazanavir has been…
